Alnus hirsuta (Spach) Rupr. Attenuates Airway Inflammation and Mucus Overproduction in a Murine Model of Ovalbumin-Challenged Asthma

Alnus hirsuta (Spach) Rupr. (AH), a member of the Betulaceae family, is widely used in Eastern Asia of as a source of medicinal compounds for the treatment of hemorrhage, diarrhea, and alcoholism. In this study, we investigated the protective effects of a methanolic extract of AH branches against airway inflammation and mucus production in tumor necrosis factor (TNF)-α-stimulated NCI-H292 cells and in an ovalbumin (OVA)-challenged allergic asthma mouse model. Female BALB/c mice were injected with OVA (40 μg) and aluminum hydroxide (2 mg) on days 0 and 14 to induce allergic airway inflammation. The mice were then challenged with 1% OVA from days 21–23. Mice were treated with AH (50 and 100 mg/kg/day; 2% DMSO) or dexamethasone (positive control; 3 mg/kg/day) from days 18–23. AH treatment effectively attenuated airway resistance/hyperresponsiveness and reduced levels of T helper type 2 (Th2) cytokines, eotaxins, and number of inflammatory cells in bronchoalveolar lavage fluid, and immunoglobulin E in serums of OVA-challenged mice. In histological analysis, AH treatment significantly inhibited airway inflammation and mucus production in OVA-challenged mice. AH treatment downregulated the phosphorylation of I kappa B-alpha, p65 nuclear factor-kappa B (p65NF-κB), and mitogen-activated protein kinases with suppression of mucin 5AC (MUC5AC) in lung tissue. Moreover, AH treatment decreased the levels of pro-inflammatory cytokines and Th2 cytokines, as well as MUC5AC expression, and inhibited the phosphorylation of p65NF-κB in TNF-α-stimulated NCI-H292 cells. These results indicate that AH might represent a useful therapeutic agent for the treatment of allergic asthma.


INTRODUCTION
Allergic asthma is a widespread global health issue characterized by chronic inflammatory disease mediated through eosinophilic inflammation, mucus overproduction, elevated allergen-specific immunoglobulin E (IgE), and airway hyperresponsiveness (LaVan et al., 2002;Park et al., 2016). It is caused by inhalation of house dust, pollen, animal dander and smoking, leading to an immune imbalance via elevation of T helper type 2 (Th2) cells in the airway (Calderon et al., 2013;Perret et al., 2013). Th2 cytokines, such as interleukin (IL)-4, , are related to the development and maintenance of allergic airway inflammation (Peebles and Aronica, 2019). Th2 cytokines recruit eosinophils and induce their infiltration and activation, as well as stimulate B cells that produce allergen-specific IgE. In particular, activated eosinophils contribute to persistent inflammation, airway hyperresponsiveness, and mucus overproduction in allergic asthma (Schatz and Rosenwasser, 2014;Lee et al., 2017). Currently, many researchers have demonstrated that the suppression of Th2 cytokines is an important target for controlling allergic asthma (Leon, 2017;Gandhi et al., 2019).
Nuclear factor-kappa B (NF-κB) is a transcription factor that plays a central role in modulating inflammatory responses . Various stimuli activate NF-κB, after which it translocate into the nucleus and binds DNA to regulate the transcription of genes involved in asthmatic responses, including those for Th2 cytokines and mucin 5AC (MUC5AC) (Cai et al., 2018;Tian et al., 2019). The mitogenactivated protein kinases (MAPKs), such as c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (Erk), and p38MAPK, are regarded as critical regulators of inflammation . In allergic asthma, the phosphorylation of MAPKs activates various transcription factors, leading to the production of proinflammatory cytokines, chemokines, and mucins (Alam and Gorska, 2011;Chauchan et al., 2018). Therefore, suppression of NF-κB and MAPK phosphorylation may constitute effective therapeutic targets for the treatment of allergic asthma. Currently, asthmatic patients are commonly treated with β 2 -agonists, bronchodilators, and corticosteroids. However, these treatments have not been successful in all patients and can cause numerous adverse effects such as growth inhibition and gastric ulcer formation (Ciriaco et al., 2013;Wise, 2014). Thus, in recent years, many researchers have investigated natural products as alternative medicines that are safer and more effective in treatment of asthma (Bang et al., 2015;Lee et al., 2019).
Alnus hirsuta (Spach) Rupr. (AH) is a deciduous tree that belongs to the Betulaceae family. It is widespread in Eastern Asia. It is used in traditional medicine for treatment of fever, diarrhea, hemorrhage, and alcoholism (Lee, 1996). Previous studies reported the beneficial effects of AH extract, including its antioxidant and anti-inflammatory activities through decreased production of reactive oxygen species (ROS) and nitric oxide (NO), and increased DPPH radical scavenging activity in lipopolysaccharide (LPS)-stimulated RAW264.7 cells (Hu and Wang, 2011). Moreover, an AH extract also inhibited cyclooxygenase (COX)-2, inducible nitric oxide synthase (iNOS) and tumor necrosis factor (TNF)-α production, through downregulation of NF-κB phosphorylation in LPSstimulated RAW264.7 cells (Jin et al., 2007). However, the effects of an extract of AH branches on airway inflammation in allergic asthma have not been investigated. Thus, we evaluated the inhibitory potential of AH on airway inflammation in TNFα-stimulated NCI-H292 cells and an ovalbumin (OVA)challenged asthmatic mouse model. To investigate the therapeutic mechanism of AH, we measured the expression levels of Th2 cytokines and mucus production via MAPKs/ p65NF-κB in the OVA-challenged asthmatic mouse model.

UPLC Q-TOF/MS Analysis
The methanol extract from the branch of A. hirsuta (Spach) Rupr. (AH), which belongs to the Betulaceae family, was collected from Gangwon Province (Gangwon-do, South Korea) and obtained from The Korea Plant Extract Bank of Korea Research Institute of Bioscience and Biotechnology (KRIBB, PB2357.6). The tentative identification of compounds in AH was analyzed by ACQUITY UPLC system coupled with Vion IMS QToF mass spectrometer (Waters Corp., Milford, MA, United States) using BEH C18 column (2.1 × 100 mm, 1.7 μm) and two mobile phases, 0.1% formic acid in water (A) and acetonitrile (B). The column and sample tray temperature were maintained at 35°C. The flow rate was 0.4 ml/min and elution conditions were optimized as follows: 0-1 min, 5% B; 1-20 min, 5-100% B; 20-20.30 min, 100% B; 20.30-22.40 min, 100-5% B; 22.40-25 min, 5% B. The mass spectrometer operated in negative mode from 100 to 1,500 Da with a 0.2 s scan time using a desolvation temperature of 350°C with desolvation gas flow of 800 L/h (N 2 ), source temperature of 110°C, and cone voltage of 40 V. Leucine-enkephalin was used as the lock mass ([M-H]m/z 554.2615). The full scan data and MS/ MS spectra were acquired using a UNIFI software (Waters Corporation, Milford, MA).

Test Compound and Reagents
The human lung epithelial cell line, NCI-H292, was purchased from American type culture collection (ATCC; Rockyville, MD, United States). Ovalbumin (OVA) and dexamethasone (DEX) were purchased from Sigma-Aldrich (St. Louis, MO, United States) and human recombinant tumor necrosis factor alpha (TNF-α) was obtained from Peprotech (Rocky Hill, NJ, United States). The enzyme-linked immunosorbent assay (ELISA) kits for IL-4, IL-5, IL-6, IL-13, TNF-α and eotaxin (R&D system, Minneapolis, MN, United States) OVA-challenged allergic asthma model was performed while using the method of Shin et al. (2019a). Mice were sensitized with 40 μg OVA with 2 mg of aluminum hydroxide gel by intraperitoneal injection on days 0 and 14. At days 18-23 after initial sensitization, mice were administered the treatments once daily by oral gavage. At the time of oral administration, mice were challenged for 1 h with OVA (1%, w/v, in PBS) using an ultrasonic nebulizer (NE-U12; OMRON Corp., Tokyo, Japan) from days 21-23. Dexamethasone was used as the positive control and was administered to mice at a dose of 3 mg/kg body weight (Shin et al., 2019a). The potential effects of AH on animal models have not been elucidated. Then, we referred to anti-inflammatory activity of Alnus genus in endotoxic shock model (Saxena et al., 2016). In addition, several studies used to 50 or 100 mg/kg of doses to investigate herbal medicine for controlling of allergic asthma (Costa et al., 2012;Shin et al., 2015;Shin et al., 2017). Thus, we selected the doses of AH 50 and 100 mg/kg.

Measurement of Airway Resistance and Airway Hyperresponsiveness
Airway resistance and airway hyperresponsiveness were evaluated by Flexivent (SCIREQ Scientific Respiratory Equipment Inc., Montreal, PQ, Canada) (Shalaby et al., 2010) 24 h after the last OVA challenge. After baseline measurements of impedance (Zrs), each animal was exposed to methacholine (5, 10 and 20 mg/ml) or PBS aerosols via a nebulizer (Aeroneb; SCIREQ) for 10 s levels of airway resistance and airway hyperresponsiveness were measured every 30 s for 1 min and refreshed for 2 min. The level of airway hyperresponsiveness was calculated by Flexivent system. The volume history of the lung was established with 6 s deep inflations to a pressure limit of 30 cmH 2 O.

Analysis of Bronchoalveolar Lavage Fluid Collection
BALF collection was performed with the method of Shin et al., (2015). Briefly, to obtain BALF, ice-cold PBS (0.7 ml) was infused into the lungs two times and withdrawn each time with a tracheal cannula (total volume, 1.4 ml). The collected BALF was centrifuged at 1,000 rpm for 10 min at 4°C. The supernatants were collected and stored at −70°C before cytokine analysis. The cell pellet was re-suspended with 500 μL ice-cold PBS and attached on a slide using a Cytospin 4 centrifuge (Thermo Scientific, Waltham, MA, USA) (1,000 rpm, 5 min, 20°C). Differential cell count was performed with Diff-Quik ® staining reagent according to the manufacturer's instructions. Five images of each slide were captured with a Leica DM5000B microscope and the Leica Application Suite acquisition software (Leica Microsystems, Wetzlar, Germany) under 40× objective lens. Thereafter, total cells, eosinophil, macrophages, and other cells (neutrophils and lymphocytes) were counted. The levels of IL-4, IL-5, IL-6, IL-13, eotaxin (R&D system), and MUC5AC (Cusabio Biotech Co.) in BALF supernatant were measured using ELISA kits, according to the manufacturer's instructions. The absorbance was measured at 450 nm using a microplate reader (iMark TM , Bio-Rad Laboratories, Richmond, CA, United States).

Analysis of Total IgE and OVA-specific IgE in Serum
The production of total IgE and OVA-specific IgE in serum were measured using ELISA kits (BioLegend) according to the manufacturer's protocols. The 96 microtiter plates were coated with OVA (10 μg/ml) and anti-IgE antibodies (anti-mouse IgE; 10 g/ml; BioLegend) in tris-buffered saline containing 0.05% Tween 20 (TBST), respectively, and incubated with a serum sample. The plates were washed four times, and 200 μL of o-phenylenediamine dihydrochloride (Sigma-Aldrich) was added to each well. The plates were incubated for 10 min in the dark, and the absorbance was measured at 450 nm using a microplate reader (Bio-Rad Laboratories).

Histopathological Examination of Lungs
After BALF collection, the lung tissue was fixed in neutralbuffered formalin, embedded in paraffin, and cut into 4 μm thick sections. To estimate the amount of airway inflammation or mucus production, the lung tissue stained with hematoxylin and eosin (H&E) (BBC Biochemical, Mount Vemon, WA) or PAS (IMEB Inc.), respectively. Quantitative analysis of airway inflammation and mucus production was performed in a blinded manner with a light microscope (Leica Microsystem) at the 10× and 20× objective lens. The degree inflammation and mucus production of each slide were graded (0, no lesions; 1, minimal; 2, mild; 3, moderate; and, 4, severe) and the index levels of inflammation and mucus production were represented as mean ± SD.

Immunoblotting in Lung Tissues
Lung tissues were homogenized (1/10, w/v) in a T-PER Tissue Protein Extraction Reagent (Thermo Scientific, Waltham, MA, United States) containing protease and phosphatase inhibitor cocktail (Thermo Scientific). The protein concentration for each samples was determined using a Bradford reagent (Bio-Rad Laboratories). Equal amounts of total protein (30 μg) were resolved by 4-12% SDS-polyacrylamide gel electrophoresis and transferred to polyvinyl difluoride membranes. Membranes were incubated with blocking solution (Thermo Scientific) followed by overnight incubation at 4°C with the following primary antibodies and dilutions: Erk, phospho (p)-Erk, JNK, p-JNK, p38MAPK, p-p38MAPK, IκB-α, p-IκB-α and β-actin (1:1,000 dilution; Cell Signaling Technology, Danvers, MA, United States), p65NF-κB, p-p65NF-κB and MUC5AC (1:1,000 dilution; Abcam, Cambridge, United Kingdom). The membranes were washed three times with Tris-buffered saline containing 0.05% Tween 20 (TBST) followed by incubation with a 1:10,000 dilution of horseradish peroxidase-conjugated secondary antibody (Cell Signaling Technology) for 1 h at room temperature. The blots were washed again three times with TBST. Protein bands were developed using an enhanced chemiluminescence kit (Thermo Scientific). Densitometric analysis for each protein band was determined using chemiluminescent scanner (LI-COR, Biosciences, Lincoln, NE, United States).

Cell Culture and Cell Viability Assay
The NCI-H292 cells were maintained in RPMI 1640 media (Gibco, San Diego, CA, United States) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco) and antibiotics at 37°C in a 5% CO 2 incubator. Cell viability after AH treatment was measured using a water-soluble tetrazolium salt 1 (WST-1; EZ-CyTox, Dogen, Republic of Korea) assay. The NCI-H292 cells were seeded in 96-well plates at a density of 5 × 10 4 cells/well, incubated in RPMI1640 (0.1% FBS) and treated with different concentrations of AH (0, 20, 40, and 80 μg/ml). After 24 h of incubation, the effect of AH on cell viability was measured by the WST-1 assay, according to the manufacturer's instructions. After the WST-1 solution was added to each well (10% of total volume) and incubated for 1 h, absorbance was measured using a microplate reader (Bio-Rad Laboratories) at 450 nm. The optical density of control cells was taken as 100% viability.

Measurement of Pro-inflammatory Cytokine Levels in TNF-α-Stimulated NCI-H292 Cells
The cells (5×10 4 cells/well) were incubated with AH at 0, 20, 40, and 80 μg/ml for 1 h before human recombinant TNF-α 30 ng/ ml. The level of TNF-α and IL-6 in culture medium were determined at 24 h incubation, after TNF-α treatment and quantified using a competitive ELISA kit (R&D system) according to the manufacturer's instructions. The absorbance at 450 nm was measured in a microplate reader (Bio-Rad Laboratories).

Immunoblotting in TNF-α-Stimulated NCI-H292 Cells
The cells (5×10 4 cells/well) were incubated with AH (0, 20, 40, and 80 μg/ml) for 1 h, followed by incubation in the presence of TNF-α (30 ng/ml). After 1 h incubation, the cells were washed with PBS and protein was collected by using M-PER Extraction Reagents (Thermo Scientific) containing protease and phosphatase inhibitor cocktail. The expression levels of p-IκBα, p-p65NF-κB and β-actin (loading control) were determined using immunoblotting as described above.

Statistical Analysis
Data are expressed as the means ± standard deviation (SD). The statistical significance of the results was determined using analysis of variance, followed by a multiple comparison test with Tukey's multiple comparison test. p values ≤0.05 were considered to be significant. Statistical analyses were performed using the GraphPad Prism 5 (GraphPad Software, CA, United States).

Effects of AH on Airway Resistance and Airway Hyperresponsiveness in OVA-Challenged Asthma Model
The OVA-challenged mice showed a significant elevation of airway resistance and airway hyperresponsiveness level in compared to normal controls at any concentration between 10 and 20 mg/ml of methacholine ( Figure 2). However, AH-treated mice had showed lower airway resistance ( Figure 2A) and airway hyperresponsiveness ( Figure 2B) than the OVA-challenged mice. These reductions were similar to those observed in DEXtreated mice.

Effects of AH on Inflammatory Cell Counts, Inflammatory Cytokines, Eotaxin and MUC5AC in the BALF of OVA-Challenged Asthma Model
As show in Figure 3A, OVA-challenged mice showed significant increases in the number of eosinophils, macrophages, and other inflammatory cells compared to the normal controls ( Figure 3A).  However, DEX and AH treatments exhibited a significant decrease in inflammatory cells, in particular eosinophils and macrophages, in a dose-dependent manner compared with the OVA-challenged mice. The levels of Th2 cytokines and eotaxins in BALF were significantly higher in OVA-challenged mice compared to the normal controls ( Figure 3B). In contrast, administration of DEX and AH decreased levels of Th2 cytokines and eotaxin compared to OVA-challenged mice. The MUC5AC level was significantly increased in OVA-challenged mice compared to the normal controls, whereas administration of DEX and AH showed a significant decrease in MUC5AC in the BALF compared with OVA-challenged mice in a dose-dependent manner.

Effects of AH on Total IgE and OVA-specific IgE in the Serum of OVA-Challenged Asthma Model
The total IgE and OVA-specific IgE levels in the serum are shown in Figure 3C. Compared to the normal controls, OVA- challenged mice displayed a significant increase in total IgE and OVA-specific IgE in serum. However, DEX and AH treatments showed the marked reduction in the total IgE and OVA-specific IgE levels in the serum compared with those of the OVA-challenged mice in a dose-dependent manner.

Effects of AH on Inflammatory Response and Mucus Production in the Lung Tissue of the OVA-Challenged Asthma Model
The OVA-challenged mice led to marked increases in infiltration of inflammatory cells into the peribronchiolar The values expressed as the means ± SD (n 7/group). ## p < 0.01, significantly different from NC group; † † p < 0.01, significantly different from OVAchallenged group.
Frontiers in Pharmacology | www.frontiersin.org February 2021 | Volume 12 | Article 614442 7 and perivascular lesions in the lung tissue ( Figure 4A). The DEX group significantly attenuated infiltration of inflammatory cells. Moreover, AH groups showed a dosedependent decrease in inflammatory cell infiltration compared with the OVA-challenged mice. Lung sections from OVA-challenged mice stained with PAS exhibited a goblet cell hyperplasia and overproduction of mucus relative to normal controls ( Figure 4B). In contrast, sections from DEX and AH groups exhibited a reduction in hyperplasia and mucus overproduction in the bronchial airway compared with OVA-challenged mice.

Effects of AH on MAPKs/p65NF-κB and MUC5AC in the Lung Tissue of the OVA-Challenged Asthma Model
The underlying mechanism of AH, we determined the effects of AH on the MAPKs, p65 NF-κB and MUC5AC expression. As shown in Figure 5, the OVA-challenged mice had a remarkable increase in the phosphorylation of MAPKs/p65NF-κB, with elevation of MUC5AC expression in the lung tissue compared to levels in normal control mice. However, treatment of DEX and AH significantly inhibited the phosphorylation of MAPKs/ p65NF-κB with reduction of MUC5AC expression in the lung tissues compared with the OVA-challenged mice.

Effects of AH on Pro-inflammatory Cytokine, Th2 Cytokines Production and p65NF-κB in TNF-α-Stimulated NCI-H292 Cells
Based on the results of cytotoxicity analysis, nontoxic concentrations (20, 40, and 80 μg/ml) of AH were employed in the present study ( Figure 6A). TNF-α (30 ng/ml) treatment markedly increased the TNF-α level compared to levels in nonstimulated cells. However, AH-treated cells had a significant decrease in levels of TNF-α and IL-6 in a concentrationdependent manner relative to TNF-α-stimulated cells ( Figures  7B,C). By analyzing the mRNA levels of the Th2 cytokines, IL-4, IL-5 and IL-13, and MUC5AC, we found that the TNFα-stimulated cells exhibited a significant increase in the mRNA levels of IL-4, IL-5, IL-13 and MUC5AC in NCI-H292 cells. Compared to TNF-α-stimulated cells, cells treated with AH had a significant reduction in the mRNA levels of the Th2 FIGURE 5 | AH inhibited phosphorylation of MAPKs/p65NF-κB and expression of MUC5AC in lung of mice 48 h after final OVA challenge. The protein levels of MAPKs/p65NF-κB and MUC5AC in the total lung tissues were determined by western blot analysis. β-actin was used to confirm equal protein loading. NC: normal control mice; OVA: OVA-challenged asthma mice; DEX: dexamethasone (3 mg/kg) + OVA-challenged asthma mice; AH: AH (50 or 100 mg/kg) + OVA-challenged asthma mice. The values are expressed as the means ± SD (n 7/group). ## p < 0.01, significantly different from NC group; †, † † p < 0.05, p < 0.01, significantly different from OVA-challenged group.

DISCUSSION
Allergic asthma is an important pulmonary disease that affects 275 million people worldwide (Huang et al., 2017). The characteristics of asthma include chronic airway inflammation, mucus overproduction and airway hyperresponsiveness, leading to airway obstruction (Halwani et al., 2010;Liu et al., 2014). Recently, there has been increased research on herbal medicines that have anti-inflammatory properties for treatment of allergic asthma (Jung et al., 2020;Liou et al., 2020). In this study, we investigated the effects of an AH extract on airway inflammation using TNF-α-stimulated NCI-H292 cells and an OVA-challenged asthmatic mouse model. Treatment with AH not only inhibited the production of TNF-α and IL-6, but also suppressed expression of IL-4, IL-5, IL-13, and MUC5AC in TNF-α-stimulated NCI-H292 cells. AH treatment markedly decreased the infiltration of inflammatory cells, particularly eosinophils and macrophages, and suppressed Th2 cytokine, eotaxin, and MUC5AC level in the BALF, as well as OVA-specific IgE in the serum of OVAchallenged asthmatic mice. AH treatment also attenuated airway resistance/hyperresponsiveness and mucus production in OVAchallenged mice. Moreover, AH effectively downregulated the phosphorylation of MAPKs/p65NF-κB, and the expression of MUC5AC in lung tissue of OVA-challenged asthmatic mice.
Frontiers in Pharmacology | www.frontiersin.org February 2021 | Volume 12 | Article 614442 9 hyperresponsiveness, airway inflammation, and mucus overproduction in OVA-challenged mice were suppressed by AH treatment. It has been demonstrated that herbal medicines with anti-inflammatory effects markedly attenuate airway inflammation and airway hyperresponsiveness via inhibition of Th2 cytokine production in the OVA-challenged asthma model (Asma et al., 2017;Sung et al., 2019). Therefore, these findings suggest that AH treatment effectively inhibited OVA-challenged allergic asthma via suppression of Th2 cytokines.
The inflammatory response during allergic asthma is due to activation of the major transcription factor NF-κB . Upon activation, IκB kinase phosphorylates NF-κB. The p65-p50 dimer of NF-κB is then translocated into the nucleus where it binds to DNA to regulate the expression of Th2 cytokines and MUC5AC in allergic asthma (Xie et al., 2015). MUC5AC is a major component of airway mucus. In asthmatic patients, MUC5AC expression is elevated by goblet cells, leading to airway limitation (Shin et al., 2019b, Song et al., 2005. In addition, MAPKs also regulate the expression of Th2 cytokines, and can affect the differentiation of inflammatory cells, such as Th2 cells and eosinophils. In a previous study, activation of MAPKs/NF-κB signaling was considered an important factor in the development of allergic asthma (Chauchan et al., 2018). In our study, AH-treated asthmatic mice exhibited a significant decrease in the phosphorylation of MAPKs/p65NF-κB and MUC5AC expression. These results are consistent with the results of our in vitro experiments. Several studies reported that blocking of MAPKs/NF-κB signaling led to significant decreases in Th2 cytokines and a reduction in mucus overproduction, leading to reduction of airway inflammation in the OVA-challenged asthmatic mouse model (Asma et al., 2017;Chauchan et al., 2018;Fengjuan et al., 2019). Thus, our results indicate that anti-asthmatic effects of AH treatment on OVAchallenged airway inflammation and mucus overproduction may be associated with inhibition of MAPKs/NF-κB, resulting in suppression of MUC5AC expression.
AH is widespread in the Eastern Asia and is used in traditional medicine as a remedy for hemorrhage, fever, and diarrhea (Lee, 1996). The AH branches were collected from Gangwon Province (Gangwon-do, South Korea) in April of 2016. The AH extracted with 99.9% methyl alcohol at room temperature and collected from The Korea Plant Extract Bank of KRIBB (PB2357.6). The AH is reported to contain rubranoside A, hirsutanonol 5-O-β-Dglucopyranoside, platyphyllenone and oregonin (Park et al., 2010). According to previous studies in LPS-stimulated RAW264.7 cells, the antioxidant effect of AH may be due to the suppression of ROS and NO production, while its antiinflammatory properties of AH include inhibition of FIGURE 7 | AH inhibited phosphorylation of p65NF-κB and IκB-α in TNF-α-stimulated NCI-H292 cells. β-actin was used to confirm equal protein loading. The culture medium were changed RPMI1640 (0.1% FBS) and treated with AH (20, 40 and 80 μg/ml) for 1 h and incubated with TNF-α (30 ng/ml) for 30 min. The values are expressed as the means ± SD (n 3). ## p < 0.01, Significantly different from control; † † p < 0.01, significantly different from TNF-α-treated group.
Frontiers in Pharmacology | www.frontiersin.org February 2021 | Volume 12 | Article 614442 inflammatory mediators and cytokines via downregulation of NF-κB (Hu and Wang, 2011;Jin et al., 2007). In our study, oregonin was the major compound of methanolic extract of AH. Oregonin inhibits the production of Th2 cytokines and IgE, as well as eosinophils in atopic dermatitis in NC/Nga mice (Choi et al., 2010). In addition, oregonin downregulates iNOS and COX-2, and decreases NO production by suppressing the NF-κB pathway (Lee et al., 2005). However, there are no reports on the protective effects of AH against allergic asthma in an in vivo model. Based on our findings, treatment with a methanolic extract of AH effectively attenuates airway inflammation and mucus overproduction by inhibiting the phosphorylation of MAPKs/p65NF-κB. In this study, AH showed protective effects in OVA-challenged asthmatic mouse model. However, these results have some limitations in our study. First, the AH was administered before OVA challenge, as opposed to after onset of asthmatic responses. This strategy would mimic a preventive procedure rather than curative procedure. Second, it has not yet been determined that the major compounds in AH have anti-inflammatory activities in the allergic asthma model. Thus, further studies will be investigated to curative effects via chronic allergic asthma model (Nials and Uddin, 2008) and evaluate to anti-inflammatory activities of oregonin in allergic asthma model for therapeutic agent of AH.

CONCLUSION
In conclusion, to the best of our knowledge, this is the first study to demonstrate that treatment with an AH attenuates airway inflammation and mucus hypersecretion by reducing Th2 cytokine release and blocking of MAPKs/p65NF-κB phosphorylation in lung tissue from OVA-challenged asthmatic mouse model. These findings suggest that methanolic extract of AH can markedly protect against allergic asthma. Thus, our results suggest that AH can be developed as a useful medicine for the treatment of allergic asthma.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT
The animal study was reviewed and approved by The Institutional Animal Care and Use Committee of the Korea Research Institute of Bioscience and Biotechnology.